Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zimberelimab + FOLFOX
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**zimberelimab + FOLFOX** is a combination investigational regimen consisting of zimberelimab, an anti-PD-1 monoclonal antibody, and FOLFOX, a standard chemotherapy regimen which includes oxaliplatin, folinic acid (leucovorin), and fluorouracil. Zimberelimab is an immune checkpoint inhibitor that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1/PD-L2 and thereby enhancing T-cell mediated anti-tumor immunity. FOLFOX is a cytotoxic chemotherapy regimen used primarily in colorectal and other gastrointestinal cancers. The combination is being evaluated in clinical trials for advanced and metastatic gastrointestinal malignancies, including gastric, gastroesophageal junction, and esophageal adenocarcinoma.
- Other names
- FOLFOXfolinic acid/fluorouracil/oxaliplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on zimberelimab + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zimberelimab + FOLFOX.